Elite in Huntington Disease

Sarah J. Tabrizi

UCL Queen Square Institute Of Neurology, 
London, ENG, GB 
Elite in Huntington Disease
UCL Queen Square Institute Of Neurology, 
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Sarah Tabrizi practices in London, United Kingdom. Ms. Tabrizi is rated as an Elite expert by MediFind in the treatment of Huntington Disease. Her top areas of expertise are Huntington Disease, Movement Disorders, Dementia, Chorea, and Gastrostomy.

Her clinical research consists of co-authoring 279 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 243 articles and participated in 2 clinical trials in the study of Huntington Disease.

Gender
Female

Locations

UCL Queen Square Institute Of Neurology, London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase Ib/II Randomized, Double-Blind Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT 130) in Early Manifest Huntington's Disease
A Phase Ib/II Randomized, Double-Blind Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT 130) in Early Manifest Huntington's Disease
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2
A Phase 2A, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease
A Phase 2A, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

276 Total Publications

Generation of C9orf72 repeat knock-in iPSC lines for modelling ALS and FTD.
Generation of C9orf72 repeat knock-in iPSC lines for modelling ALS and FTD.
Journal: bioRxiv : the preprint server for biology
Published: October 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Tabrizi's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile